Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?

Authors: Csermely A, Mantovani A, Morieri ML et al.
Published in Diabetes & Metabolism (September 2023)
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), affects 30% of adults worldwide and up to 40% of those with type 1 diabetes mellitus (T1DM)
Read MoreMultiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?

Research Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient Care

Authors: Iruzubieta P, Bataller R, Arias-Loste MT et al.
Published in Clinics in Liver Disease (May 2023)
Both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), NAFLD’s inflammatory and progressive subtype, are the histologic manifestations of a heterogeneous disease intricately linked with metabolic disorders.
Read MoreResearch Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient Care

The Long Road to NASH Therapeutics: Uncovering Valuable Insights

Authors: Tilg H, Byrne CD and Targher G
Published in The Lancet Gastroenterology and Hepatology (October 2023)
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are affected by non-alcoholic fatty liver disease (NAFLD).
Read MoreThe Long Road to NASH Therapeutics: Uncovering Valuable Insights

Liver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?

Authors: Ciardullo S, Muraca E, Zerbini F et al.
Published in Liver International (September 2023)
Liver-related events contribute to a small proportion of mortality within the collective cohort of patients with non-alcoholic fatty liver disease (NAFLD).
Read MoreLiver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?

NAFLD and Pancreatic Steatosis: A Bidirectional Relationship?

Authors: Wongtrakul W, Untaaveesup S, Pausawadi N et al.
Published in European Journal of Gastroenterology & Hepatology (October 2023)
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
Read MoreNAFLD and Pancreatic Steatosis: A Bidirectional Relationship?

Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Authors: Pais R, Cariou B, Noureddin M et al.
Published in Journal of Hepatology (September 2023)
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Read MoreManaging Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

Authors: Tacke F, Puengel T, Loomba R et al.
Published in Journal of Hepatology (August 2023)
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Read MoreExploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Authors: Fromenty B, Roden M
Published in Journal of Hepatology (February 2023)
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Read MoreExamining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Insights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?

Authors: Chew NWS, Ng CH, Tan DJH et al.
Published in Cell Metabolism (March 2023)
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver disease (NAFLD), accounts for a significant proportion of this burden.
Read MoreInsights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?

NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?

Authors: Sanyal AJ, Magnanensi J, Majd Z et al.
Published in Hepatology Communications (September 2023)
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
Read MoreNIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES